Novartis is abandoning the experimental drug pelacarsen after a study found it failed to reduce heart attacks, strokes, or cardiovascular deaths
Health – 4 outlets
Bloomberg
Novartis Abandons Heart Drug After Surprising Failure in Key Study
CNN
A promising drug for an inherited heart risk flops, stunning doctors
CTV News
A promising drug for an inherited heart risk flops, stunning doctors seen
STAT
STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy